CD8A and neoplasm: Nevertheless, checkpoint inhibition is only effective in patients with a pre-existing tumor-reactive CD8+ T cell response, limiting its clinical applicability to certain tumor types and stages, if other means to provide tumor-reactive T cells are not applied [16].